Literature DB >> 422706

Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.

M Sheppard, B Shapiro, B Pimstone, S Kronheim, M Berelowitz, M Gregory.   

Abstract

The MCR and half-disappearance time of exogenously administered somatostatin have been measured during and after cessation of a constant infusion. Studies were performed on normal volunteers and patients with chronic liver disease and failure. Immunoreactive somatostatin was measured by a sensitive and specific RIA using an antiserum directed against the core of the molecule. Normal subjects had a mean MCR of 1949 +/- 250 ml/min (28.4 +/- 4.2 ml/min . kg BW) (mean +/- SEM), similar to values found in five patients with chronic liver disease. However, patients with chronic renal failure showed a highly significant (P less than 0.001) lowering of the MCR (501 +/- 32.7 ml/min or 7.8 +/- 0.6 ml/min . kg). The rate of disappearance of somatostatin after infusion was linear for 7-10 min, after which a much slower component was observed. In normal subjects, the t 1/2 of the first component varied from 1.1-3.0 min, in patients with liver disease it varied from 1.2-4.8 min, and in patients with chronic renal failure it varied from 2.6-4.9 min. Exogenously administered somatostatin is rapidly cleared in normal subjects and patients with chronic liver disease, but the MCR in end stage chronic renal failure is markedly lowered. The kidney may have a role in the metabolic clearance of exogenously administered somatostatin, or uremia may impair catabolism nonspecifically.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 422706     DOI: 10.1210/jcem-48-1-50

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.

Authors:  L A Frohman; T R Downs; T C Williams; E P Heimer; Y C Pan; A M Felix
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Stability of somatostatin in total parenteral nutrition.

Authors:  J B Montoro; R Galard; R Catalan; J Martinez; P Salvador; P Sabin
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

3.  Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats.

Authors:  C Chen; G M Pollack
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 4.  Somatostatin in portal hypertension.

Authors:  J S Morgan; R J Groszmann
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

Review 5.  Enterocutaneous Fistula: Proven Strategies and Updates.

Authors:  Irena Gribovskaja-Rupp; Genevieve B Melton
Journal:  Clin Colon Rectal Surg       Date:  2016-06

6.  Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

Authors:  L A Frohman; J L Thominet; C B Webb; M L Vance; H Uderman; J Rivier; W Vale; M O Thorner
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

7.  Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects.

Authors:  M E Kraenzlin; S M Wood; M Neufeld; T E Adrian; S R Bloom
Journal:  Experientia       Date:  1985-06-15

8.  Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.

Authors:  R G Long; J R Peters; S R Bloom; M R Brown; W Vale; J E Rivier; D G Grahame-Smith
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

9.  Differential pulsatile secretagogue control of GH secretion in healthy men.

Authors:  Catalina Norman; John Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

10.  Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995.

Authors:  H S Füessl; W G Zoller; M M Kochen; J R Bogner; B Heinrich; A Matuschke; F D Goebel
Journal:  Klin Wochenschr       Date:  1989-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.